Simon Douglas, Chairman

Over 20 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation in 2004. Currently Simon is a non-executive director of the antibody-based therapeutics Company Fusion Antibodies, where he was previously the CEO, and also the Chief Executive of the diagnostic company Xynostics Ltd.